Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer

Tian Zhang • 1 Jun 2026
ASCO 2026
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Pembrolizumab

Tian Zhang, MD, of UT Southwestern Medical Center, discusses evolving treatment sequencing strategies following frontline enfortumab vedotin (EV) plus pembrolizumab in metastatic bladder cancer, highlighting mechanisms of antibody-drug conjugate (ADC) resistance and the emerging role of alternative targets including TROP2 and HER2. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tian Zhang

Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
1:51
BOOST-RCC: evolocumab and nivolumab in metastatic renal cell carcinoma
Tian Zhang • 28 Feb 2026
Overcoming resistance to frontline immunotherapy in kidney cancer
0:57
Overcoming resistance to frontline immunotherapy in kidney cancer
Tian Zhang • 28 Feb 2026

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals